Effect of PRP Joint Cavity Combined with Acupoint Injection on Osteoarthritis of Knee Joint

Plain-language summary

This study examined the combined effect of intra-articular platelet-rich plasma (PRP) and acupoint injection in patients with knee osteoarthritis. Patients with early-stage knee osteoarthritis, chronic joint pain or swelling, and meeting certain X-ray criteria were included. It was a non-phase study that has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Not Applicable

Status

Completed

Sponsor

Zhengzhou Revo-Gene Technology Co., LTD

Intervention

PRP joint injection combined with acupoint injection

Start date

4/10/2023

Estimated completion

4/10/2023

Countries

China

Related genes

Locations

• Zhengzhou, China

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

1. The expected survival period is more than 3 months;
2. The clinical diagnosis was early knee osteoarthritis;
3. Capable of knee injections;
4. chronic joint pain or swelling (\> 4 months);
5. It meets the diagnostic criteria of the Chinese Guidelines for the Diagnosis and Treatment of Osteoarthritis (2021 Edition) , and the X-ray evaluation results meet the Kellgren-Lawrence scale (K-L scale) level I to level III.

Exclusion Criteria:

1. age over 80 years old;
2. K-L classification is greater than Ⅲ grade;
3. Combined with rheumatoid arthritis, severe osteoporosis, tumor, gout, obvious joint deformity and other diseases;
4. Poor compliance, not according to the provisions of treatment;
5. Pregnant and lactating women;
6. Patients voluntarily withdrew from the study;
7. Patients were lost to follow-up due to various reasons during follow-up.